Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity.
19,176 Deaths · 90,793 Hospitalizations · 119,875 Urgent Care · 201,379 Doctor Office Visits · 2,549 Anaphylaxis · 6,399 Bell's Palsy · 2,071 Miscarriages · 9,512 Heart Attacks · 28,814 Myocarditis · 18,686 Permanently Disabled · 9,347 Thrombocytopenia · 15,437 Life Threatening · 36,950 Severe Allergic Reaction · 8,257 Shingles · 5,326 Myocarditis/Pericarditis · 3,736 Thrombocytopenia/Low Platelet ·
·
19,176 Deaths · 90,793 Hospitalizations · 119,875 Urgent Care · 201,379 Doctor Office Visits · 2,549 Anaphylaxis · 6,399 Bell's Palsy · 2,071 Miscarriages · 9,512 Heart Attacks · 28,814 Myocarditis · 18,686 Permanently Disabled · 9,347 Thrombocytopenia · 15,437 Life Threatening · 36,950 Severe Allergic Reaction · 8,257 Shingles · 5,326 Myocarditis/Pericarditis · 3,736 Thrombocytopenia/Low Platelet ·
·